{"gene":"APOE","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":2008,"finding":"ApoE facilitates the proteolytic clearance of soluble Aβ from the brain: endolytic degradation of Aβ within microglia by neprilysin is dramatically enhanced by ApoE, and extracellular Aβ degradation by insulin-degrading enzyme is also facilitated by ApoE. This capacity depends on ApoE isoform and lipidation status. Activation of liver X receptors (LXR) increases lipidated ApoE and stimulates Aβ degradation in vivo.","method":"In vitro degradation assays with microglia and purified enzymes; LXR agonist treatment of Tg2576 mice with measurement of brain Aβ load and contextual memory","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal in vitro and in vivo methods, replicated across enzyme systems and cellular contexts in a single rigorous study","pmids":["18549781"],"is_preprint":false},{"year":2013,"finding":"ApoE does not directly bind soluble Aβ to an appreciable extent in solution or in human CSF. Instead, apoE regulates soluble Aβ metabolism by competing with Aβ for LRP1-dependent cellular uptake in astrocytes, thereby modulating Aβ clearance without requiring direct apoE–Aβ complex formation in extracellular fluids.","method":"Multiple biochemical and analytical techniques (SEC, native PAGE, SPR); brain Aβ microdialysis in mice receiving apoE infusions; LRP1 competition assays in astrocytes","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal biochemical methods plus in vivo microdialysis; rigorous negative result on direct binding and positive mechanistic result on LRP1 competition","pmids":["23620513"],"is_preprint":false},{"year":1999,"finding":"ApoE3, but not ApoE4, protects against excitotoxin-induced and age-dependent neurodegeneration in mouse brain. Expression of human apoE3 in Apoe-/- mice preserved synaptophysin-positive presynaptic terminals, MAP2-positive dendrites, and neurofilament-positive axons after kainic acid challenge, whereas apoE4 did not.","method":"Neuron-specific enolase promoter-driven expression of human apoE3 or apoE4 in Apoe-/- mice; kainic acid challenge; immunohistochemical quantification of synaptic and dendritic markers","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic rescue experiment in defined knockout background with multiple immunohistochemical readouts, isoform-specific phenotype","pmids":["10366621"],"is_preprint":false},{"year":2019,"finding":"All human ApoE isoforms directly inhibit the classical complement cascade (CCC) by binding with high affinity (KD ~140–580 pM) to activated C1q, forming ApoE–C1q complexes. In ApoE-deficient mice, oxidized lipids activate the CCC, causing leukocyte infiltration; ApoE suppresses this by acting as a direct checkpoint inhibitor of complement activation.","method":"In vitro binding assays (SPR/biophysical measurement of KD); immunostaining of C1q-ApoE complexes in human and mouse tissue; siRNA knockdown of C5 in mice; analysis of ApoE-/- mouse choroid plexus inflammation","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct binding measured with KD determination, multiple in vivo models, human tissue validation, orthogonal siRNA intervention","pmids":["30692699"],"is_preprint":false},{"year":1999,"finding":"Truncated ApoE (22 kDa N-terminal fragment) and ApoE-derived peptides cause neurotoxicity and increases in intracellular calcium in embryonic rat hippocampal neurons. The calcium influx and cell death are reduced by receptor-associated protein (RAP), removal of extracellular calcium, or the NMDA receptor antagonist MK-801, indicating involvement of cell-surface receptors including NMDA receptors.","method":"Primary embryonic rat hippocampal neuron culture; intracellular calcium imaging; pharmacological inhibition with RAP and MK-801; protease inhibitor experiments","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological tools in primary neurons, single lab, no structural or reconstitution confirmation","pmids":["10436064"],"is_preprint":false},{"year":2004,"finding":"ApoE3 forms a direct complex with ABCA1 on the surface of intact fibroblasts. Lipid-free apoE3 competes with apoA-I for ABCA1 binding and promotes ABCA1-dependent cholesterol efflux. This interaction generates nascent apoE/cholesterol/phospholipid particles of 9–15 nm with prebeta electrophoretic mobility. A Tangier disease mutation in ABCA1 (C1477R) abolishes both apoE3 binding and apoE3-mediated cholesterol efflux, demonstrating that ABCA1 is essential for biogenesis of apoE-containing HDL-sized particles.","method":"125I-apoA-I competition binding assays; cholesterol efflux assays with ABCA1 mutant cells; native PAGE sizing of nascent particles; stimulated intact human fibroblasts","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct binding competition, functional efflux assay, mutant-rescue design, particle characterization by PAGE; multiple orthogonal methods in single study","pmids":["14754908"],"is_preprint":false},{"year":2022,"finding":"APOE accumulation in aged human mesenchymal progenitor cells (MPCs) drives cellular senescence by destabilizing heterochromatin. Mechanistically, increased APOE causes autophagy-lysosomal pathway-dependent degradation of nuclear lamina proteins and the heterochromatin-associated protein KAP1 (KRAB-associated protein 1), thereby disrupting heterochromatin organization. CRISPR-Cas9 deletion of APOE confers resistance to senescence in human MPCs.","method":"CRISPR-Cas9 knockout of APOE in human MPCs; stress-induced and physiological aging models; immunoblot and immunofluorescence for lamin and KAP1; autophagy-lysosome pathway inhibition experiments","journal":"Nature aging","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic CRISPR deletion with defined molecular mechanism (autophagy-lysosomal degradation of heterochromatin proteins), multiple cell models and orthogonal methods","pmids":["37117743"],"is_preprint":false},{"year":2024,"finding":"Lipidated ApoE2 (lipApoE2) has impaired binding to the LDL receptor (LDLR) compared with lipApoE3/4, which avoids LDLR recycling defects and reduces uptake of cholesteryl esters (CEs) into neurons. In human neurons, ApoE carrying polyunsaturated fatty acid-CE (PUFA-CE) causes lysosomal lipofuscinosis in an allelic series (ApoE4 > ApoE3 > ApoE2); lipofuscin accumulation promotes lysosomal retention of tau fibrils. The protective Christchurch mutation also reduces LDLR binding and phenocopies ApoE2. Intrahippocampal injection of PUFA-CE-lipApoE4 alone is sufficient to induce lipofuscinosis in wild-type mice.","method":"iPSC-derived human neurons; LDLR binding assays; cholesteryl ester uptake measurements; lipofuscin quantification; tau fibril lysosomal assay; intrahippocampal injection in mice; 5xFAD mouse brain analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — reconstitution in human neurons with isoform series, in vivo injection sufficiency experiment, mutant (Christchurch) phenocopy, multiple orthogonal assays in one rigorous study","pmids":["39532095"],"is_preprint":false},{"year":2023,"finding":"Mitochondrial dysfunction (genetic disruption of SLC25A transporters or pharmacological/genetic inhibition of electron transport chain complexes I, III, or IV) causes upregulation of APOE transcript, protein, and secretion (up to 49-fold) in diverse cell types including iPSC-derived human astrocytes, as part of an inflammatory gene expression program. Age- and genotype-dependent decline in respiratory complex I preceded increased APOE in the 5xFAD mouse brain.","method":"Gene editing of SLC25A transporters; pharmacological ETC inhibition; iPSC-derived astrocytes; qRT-PCR and ELISA for APOE; 5xFAD mouse brain immunoblots","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple genetic and pharmacological perturbations in multiple cell types, single lab, no direct mechanistic link elucidated between ETC and APOE transcription","pmids":["37171075"],"is_preprint":false},{"year":2013,"finding":"The structure of full-length apoE3 (two-domain protein, 34 kDa) was determined and showed that mutations in the N-terminal domain can be propagated through the structure to the C-terminal domain. The single amino acid difference between apoE3 and apoE4 underlies structural differences relevant to their distinct disease-related functions.","method":"Review/analysis of 2011 structure determination; structural interpretation of isoform differences","journal":"Protein science : a publication of the Protein Society","confidence":"Low","confidence_rationale":"Tier 4 / Weak — this abstract is a review/perspective that references a 2011 structure paper without presenting new experimental data; structural claim cannot be directly verified from this abstract","pmids":["24115173"],"is_preprint":false},{"year":2024,"finding":"ApoE variants affecting VLDL binding affinity to the LDL receptor were directly assayed in vitro. Variants p.(Arg163Cys) and p.(Arg165Trp) showed intermediate LDLR affinity between APOE2/2 and APOE3/3, while p.(Gly145Asp) and p.(Pro220Leu) showed higher affinity than APOE3/3, demonstrating that specific APOE coding variants alter receptor-binding function and contribute to dysbetalipoproteinemia.","method":"In vitro VLDL-to-LDLR binding affinity assay with patient-derived variants; NMR lipoprotein particle analysis","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct in vitro receptor binding assay with functional implication, but single lab and limited mechanistic follow-up","pmids":["37051929"],"is_preprint":false},{"year":2016,"finding":"PCSK9 increases hepatic lipid and lipoprotein production via mechanisms dependent on both LDLR and apoE. In transgenic mice expressing human PCSK9 on an apoE-null background, the lipid-raising effect of PCSK9 is abolished, demonstrating that apoE is required for PCSK9-mediated hepatic lipogenesis and dyslipidemia.","method":"Transgenic hPCSK9 mice on WT, LDLR-/-, and apoE-/- backgrounds; plasma lipid measurement; hepatic gene expression analysis","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis using defined knockout backgrounds, multiple lipid and gene expression readouts, single lab","pmids":["26980204"],"is_preprint":false},{"year":2000,"finding":"Somatic gene transfer of human APOE cDNA via adenoviral vector into ApoE-deficient nude mice restored plasma apoE secretion, normalized hypercholesterolemia within 14 days, and induced dose-dependent regression of pre-existing fatty streak lesions in the aorta, demonstrating that apoE expression is sufficient to reverse atherosclerotic lesions.","method":"Adenoviral gene transfer into ApoE-/- nude mice; plasma cholesterol and triglyceride measurement; aortic lesion quantification","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic rescue experiment with defined functional outcome (lesion regression), single lab","pmids":["10669641"],"is_preprint":false}],"current_model":"ApoE is a secreted lipid transport protein that facilitates Aβ clearance through LRP1-dependent pathways and protease-mediated degradation in the brain, directly inhibits classical complement activation via high-affinity C1q binding, promotes cholesterol efflux through ABCA1 interaction and lipidated-particle formation, regulates neuronal cholesterol/lipid uptake via LDLR with isoform-dependent pathogenicity (ApoE4 > ApoE3 > ApoE2), drives cellular senescence by destabilizing heterochromatin through autophagy-lysosomal degradation of lamin and KAP1, and is transcriptionally upregulated as part of an inflammatory program downstream of mitochondrial dysfunction; isoform-specific differences in receptor binding, lipidation, and structural domain communication underlie the differential risk of Alzheimer's disease and cardiovascular disease conferred by the ε2, ε3, and ε4 alleles."},"narrative":{"mechanistic_narrative":"ApoE is a secreted, two-domain lipid transport protein that governs cholesterol and lipoprotein trafficking in the periphery and brain, with allele-specific structural differences (ε2/ε3/ε4) translating into differential disease risk [PMID:24115173]. In lipid handling, lipid-free ApoE3 binds ABCA1 directly, competes with apoA-I, and drives ABCA1-dependent cholesterol efflux to form nascent 9–15 nm prebeta HDL-sized particles [PMID:14754908], while lipidated ApoE engages the LDL receptor in an isoform-graded manner that controls neuronal cholesteryl-ester uptake; impaired LDLR binding by ApoE2 and the Christchurch mutation reduces uptake and is protective, whereas ApoE4 promotes lysosomal lipofuscinosis and retention of tau fibrils (ApoE4 > ApoE3 > ApoE2) [PMID:39532095]. In Aβ metabolism, ApoE does not appreciably bind soluble Aβ directly but instead competes with Aβ for LRP1-dependent cellular uptake in astrocytes [PMID:23620513] and enhances proteolytic Aβ degradation by neprilysin and insulin-degrading enzyme in a lipidation-dependent manner stimulated by LXR activation [PMID:18549781]. ApoE also acts as a high-affinity checkpoint inhibitor of the classical complement cascade by binding activated C1q (KD ~140–580 pM), suppressing complement-driven leukocyte infiltration [PMID:30692699], and ApoE3 (but not ApoE4) preserves synaptic, dendritic, and axonal integrity against excitotoxic neurodegeneration [PMID:10366621]. In aged mesenchymal progenitor cells, APOE accumulation drives cellular senescence by promoting autophagy-lysosomal degradation of nuclear lamina proteins and KAP1, destabilizing heterochromatin [PMID:37117743], and APOE is transcriptionally upregulated as part of an inflammatory program downstream of mitochondrial/electron-transport-chain dysfunction [PMID:37171075]. Peripherally, ApoE expression is sufficient to reverse hypercholesterolemia and atherosclerotic lesions in ApoE-deficient mice [PMID:10669641], is required for PCSK9-mediated hepatic lipogenesis [PMID:26980204], and specific coding variants alter LDLR binding affinity and contribute to dysbetalipoproteinemia [PMID:37051929].","teleology":[{"year":1999,"claim":"Established that ApoE protects against neurodegeneration in an isoform-specific manner, framing ApoE3 as neuroprotective and ApoE4 as deficient in this protection.","evidence":"Neuron-specific expression of human apoE3 or apoE4 in Apoe-/- mice with kainic acid challenge and immunohistochemical quantification of synaptic/dendritic/axonal markers","pmids":["10366621"],"confidence":"High","gaps":["Molecular mechanism of ApoE3 neuroprotection not defined","Does not connect protection to a specific receptor or lipid pathway"]},{"year":1999,"claim":"Showed that truncated ApoE fragments are directly neurotoxic via receptor- and calcium-dependent mechanisms, implicating ApoE proteolysis in neuronal injury.","evidence":"Primary embryonic rat hippocampal neuron culture with calcium imaging and pharmacological inhibition (RAP, MK-801)","pmids":["10436064"],"confidence":"Medium","gaps":["Single lab without structural or reconstitution confirmation","Identity of the cell-surface receptor mediating toxicity not pinned down","Relevance of fragment generation in vivo unclear"]},{"year":2000,"claim":"Demonstrated that ApoE expression is sufficient not only to correct hypercholesterolemia but to reverse pre-existing atherosclerotic lesions, establishing causal sufficiency for vascular protection.","evidence":"Adenoviral APOE gene transfer into ApoE-/- nude mice with plasma lipid and aortic lesion quantification","pmids":["10669641"],"confidence":"Medium","gaps":["Single lab","Does not isolate which ApoE function (clearance vs efflux) drives regression","No isoform comparison"]},{"year":2004,"claim":"Identified ABCA1 as a direct ApoE3 binding partner mediating cholesterol efflux and biogenesis of nascent ApoE-HDL particles, linking ApoE to reverse cholesterol transport machinery.","evidence":"125I-apoA-I competition binding, cholesterol efflux assays in ABCA1 mutant (Tangier C1477R) fibroblasts, and native PAGE particle sizing","pmids":["14754908"],"confidence":"High","gaps":["Isoform dependence of ABCA1 binding not fully resolved","Structural basis of ApoE-ABCA1 interaction unknown"]},{"year":2008,"claim":"Established that ApoE facilitates proteolytic Aβ clearance in a lipidation-dependent manner, connecting ApoE lipid state and LXR signaling to amyloid degradation.","evidence":"In vitro degradation assays with microglia/purified neprilysin and IDE, plus LXR agonist treatment of Tg2576 mice with brain Aβ and memory readouts","pmids":["18549781"],"confidence":"High","gaps":["Quantitative isoform contributions to clearance not separated","Whether effect is direct enzyme modulation or substrate presentation unclear"]},{"year":2013,"claim":"Resolved the mechanism of ApoE-Aβ interaction by showing ApoE does not bind soluble Aβ directly but competes for LRP1-mediated uptake, reframing ApoE as a clearance modulator rather than an Aβ chaperone.","evidence":"SEC, native PAGE, SPR biochemistry plus in vivo brain Aβ microdialysis and astrocyte LRP1 competition assays","pmids":["23620513"],"confidence":"High","gaps":["Isoform differences in LRP1 competition not quantified here","Relationship to proteolytic clearance pathway not integrated"]},{"year":2013,"claim":"Provided the structural rationale for isoform effects by showing the full-length two-domain ApoE3 structure propagates N-terminal mutations to the C-terminal domain.","evidence":"Review/analysis of a prior structure determination of full-length apoE3","pmids":["24115173"],"confidence":"Low","gaps":["Review/perspective without new experimental data; structural claim not directly verifiable from this source","No direct functional mapping of domain communication to receptor binding"]},{"year":2016,"claim":"Placed ApoE genetically downstream of PCSK9 by showing ApoE is required for PCSK9-driven hepatic lipogenesis, defining an ApoE-dependent arm of dyslipidemia.","evidence":"Transgenic hPCSK9 mice on WT, LDLR-/-, and apoE-/- backgrounds with plasma lipid and hepatic expression analysis","pmids":["26980204"],"confidence":"Medium","gaps":["Mechanism by which ApoE enables PCSK9-driven lipogenesis not defined","Single lab"]},{"year":2019,"claim":"Revealed a non-lipid function of ApoE as a high-affinity inhibitor of the classical complement cascade through direct C1q binding, establishing ApoE as a complement checkpoint.","evidence":"SPR KD determination, C1q-ApoE complex immunostaining in human/mouse tissue, C5 siRNA knockdown, and ApoE-/- choroid plexus inflammation analysis","pmids":["30692699"],"confidence":"High","gaps":["Isoform-specific differences in C1q inhibition not delineated","Structural basis of ApoE-C1q binding unresolved"]},{"year":2022,"claim":"Uncovered a cell-intrinsic pro-senescence role for APOE, showing its accumulation destabilizes heterochromatin via autophagy-lysosomal degradation of lamin and KAP1.","evidence":"CRISPR-Cas9 APOE knockout in human MPCs, aging/stress models, immunoblot/immunofluorescence for lamin and KAP1, and autophagy-lysosome inhibition","pmids":["37117743"],"confidence":"High","gaps":["How secreted/intracellular APOE triggers lysosomal targeting of nuclear proteins is unclear","Isoform dependence of senescence phenotype not addressed"]},{"year":2023,"claim":"Identified mitochondrial/ETC dysfunction as an upstream driver of APOE induction, placing APOE within an inflammatory transcriptional response to bioenergetic stress.","evidence":"Gene editing of SLC25A transporters and ETC inhibition in iPSC-derived astrocytes and other cells with qRT-PCR/ELISA, plus 5xFAD mouse brain immunoblots","pmids":["37171075"],"confidence":"Medium","gaps":["Direct transcriptional link between ETC state and APOE promoter not elucidated","Single lab"]},{"year":2024,"claim":"Connected isoform-graded LDLR binding to neuronal lipid pathology, showing impaired LDLR binding (ApoE2, Christchurch) is protective while ApoE4 promotes lysosomal lipofuscinosis and tau fibril retention.","evidence":"iPSC-derived human neurons with LDLR binding and cholesteryl ester uptake assays, lipofuscin and tau fibril readouts, and intrahippocampal PUFA-CE-lipApoE4 injection in mice","pmids":["39532095"],"confidence":"High","gaps":["Mechanism linking lipofuscin to tau retention not fully resolved","Generalizability of injection sufficiency to physiological aging unclear"]},{"year":2024,"claim":"Demonstrated that specific APOE coding variants quantitatively shift LDLR binding affinity, providing functional grounding for variant contributions to dysbetalipoproteinemia.","evidence":"In vitro VLDL-to-LDLR binding affinity assays with patient-derived variants and NMR lipoprotein particle analysis","pmids":["37051929"],"confidence":"Medium","gaps":["Single lab with limited mechanistic follow-up","In vivo consequences of intermediate-affinity variants not established"]},{"year":null,"claim":"How a single protein integrates lipid transport, receptor binding, complement inhibition, and chromatin-destabilizing senescence into the allele-specific risk for Alzheimer's and cardiovascular disease remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified structural-functional model linking isoform differences across all described activities","Relative contribution of each pathway to disease risk in vivo undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[5,7]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[3,0]},{"term_id":"GO:0140104","term_label":"molecular carrier activity","supporting_discovery_ids":[5,7,12]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[1,3,8]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[7]}],"pathway":[],"complexes":[],"partners":["ABCA1","LRP1","LDLR","C1Q","APOA1","PCSK9"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P02649","full_name":"Apolipoprotein E","aliases":[],"length_aa":317,"mass_kda":36.2,"function":"APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids (PubMed:14754908, PubMed:1911868, PubMed:6860692). APOE is a core component of plasma lipoproteins and is involved in their production, conversion and clearance (PubMed:14754908, PubMed:1911868, PubMed:1917954, PubMed:23620513, PubMed:2762297, PubMed:6860692, PubMed:9395455). Apolipoproteins are amphipathic molecules that interact both with lipids of the lipoprotein particle core and the aqueous environment of the plasma (PubMed:2762297, PubMed:6860692, PubMed:9395455). As such, APOE associates with chylomicrons, chylomicron remnants, very low density lipoproteins (VLDL) and intermediate density lipoproteins (IDL) but shows a preferential binding to high-density lipoproteins (HDL) (PubMed:1911868, PubMed:6860692). It also binds a wide range of cellular receptors including the LDL receptor/LDLR, the LDL receptor-related proteins LRP1, LRP2 and LRP8 and the very low-density lipoprotein receptor/VLDLR that mediate the cellular uptake of the APOE-containing lipoprotein particles (PubMed:12950167, PubMed:1530612, PubMed:1917954, PubMed:20030366, PubMed:20303980, PubMed:2063194, PubMed:2762297, PubMed:7635945, PubMed:7768901, PubMed:8756331, PubMed:8939961). Finally, APOE also has a heparin-binding activity and binds heparan-sulfate proteoglycans on the surface of cells, a property that supports the capture and the receptor-mediated uptake of APOE-containing lipoproteins by cells (PubMed:23676495, PubMed:7635945, PubMed:9395455, PubMed:9488694). A main function of APOE is to mediate lipoprotein clearance through the uptake of chylomicrons, VLDLs, and HDLs by hepatocytes (PubMed:1911868, PubMed:1917954, PubMed:23676495, PubMed:29516132, PubMed:9395455). APOE is also involved in the biosynthesis by the liver of VLDLs as well as their uptake by peripheral tissues ensuring the delivery of triglycerides and energy storage in muscle, heart and adipose tissues (PubMed:2762297, PubMed:29516132). By participating in the lipoprotein-mediated distribution of lipids among tissues, APOE plays a critical role in plasma and tissues lipid homeostasis (PubMed:1917954, PubMed:2762297, PubMed:29516132). APOE is also involved in two steps of reverse cholesterol transport, the HDLs-mediated transport of cholesterol from peripheral tissues to the liver, and thereby plays an important role in cholesterol homeostasis (PubMed:14754908, PubMed:23620513, PubMed:9395455). First, it is functionally associated with ABCA1 in the biogenesis of HDLs in tissues (PubMed:14754908, PubMed:23620513). Second, it is enriched in circulating HDLs and mediates their uptake by hepatocytes (PubMed:9395455). APOE also plays an important role in lipid transport in the central nervous system, regulating neuron survival and sprouting (PubMed:25173806, PubMed:8939961). APOE is also involved in innate and adaptive immune responses, controlling for instance the survival of myeloid-derived suppressor cells (By similarity). Binds to the immune cell receptor LILRB4 (PubMed:30333625). APOE may also play a role in transcription regulation through a receptor-dependent and cholesterol-independent mechanism, that activates MAP3K12 and a non-canonical MAPK signal transduction pathway that results in enhanced AP-1-mediated transcription of APP (PubMed:28111074) (Microbial infection) Through its interaction with HCV envelope glycoprotein E2, participates in the attachment of HCV to HSPGs and other receptors (LDLr, VLDLr, and SR-B1) on the cell surface and to the assembly, maturation and infectivity of HCV viral particles (PubMed:25122793, PubMed:29695434). This interaction is probably promoted via the up-regulation of cellular autophagy by the virus (PubMed:29695434)","subcellular_location":"Secreted; Secreted, extracellular space; Secreted, extracellular space, extracellular matrix; Extracellular vesicle; Endosome, multivesicular body","url":"https://www.uniprot.org/uniprotkb/P02649/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/APOE","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/APOE","total_profiled":1310},"omim":[{"mim_id":"619429","title":"TRANSMEMBRANE AND COILED-COIL DOMAIN FAMILY, MEMBER 2; TMCC2","url":"https://www.omim.org/entry/619429"},{"mim_id":"619324","title":"HYPERTRIGLYCERIDEMIA 2; HYTG2","url":"https://www.omim.org/entry/619324"},{"mim_id":"618983","title":"BLOOD GROUP, LEWIS SYSTEM; LE","url":"https://www.omim.org/entry/618983"},{"mim_id":"618666","title":"SITOSTEROLEMIA 2; STSL2","url":"https://www.omim.org/entry/618666"},{"mim_id":"618055","title":"CELLULAR REPRESSOR OF E1A-STIMULATED GENES 1; CREG1","url":"https://www.omim.org/entry/618055"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"adrenal gland","ntpm":3391.3},{"tissue":"brain","ntpm":2714.9},{"tissue":"liver","ntpm":6533.9}],"url":"https://www.proteinatlas.org/search/APOE"},"hgnc":{"alias_symbol":[],"prev_symbol":["AD2"]},"alphafold":{"accession":"P02649","domains":[{"cath_id":"1.20.120.20","chopping":"34-207","consensus_level":"high","plddt":86.5056,"start":34,"end":207}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P02649","model_url":"https://alphafold.ebi.ac.uk/files/AF-P02649-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P02649-F1-predicted_aligned_error_v6.png","plddt_mean":75.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=APOE","jax_strain_url":"https://www.jax.org/strain/search?query=APOE"},"sequence":{"accession":"P02649","fasta_url":"https://rest.uniprot.org/uniprotkb/P02649.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P02649/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P02649"}},"corpus_meta":[{"pmid":"18549781","id":"PMC_18549781","title":"ApoE promotes the proteolytic degradation of Abeta.","date":"2008","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/18549781","citation_count":736,"is_preprint":false},{"pmid":"23620513","id":"PMC_23620513","title":"ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23620513","citation_count":457,"is_preprint":false},{"pmid":"10366621","id":"PMC_10366621","title":"Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration.","date":"1999","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/10366621","citation_count":286,"is_preprint":false},{"pmid":"30692699","id":"PMC_30692699","title":"ApoE attenuates unresolvable inflammation by complex formation with activated C1q.","date":"2019","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30692699","citation_count":238,"is_preprint":false},{"pmid":"922890","id":"PMC_922890","title":"The initiation sites for RNA transcription in Ad2 DNA.","date":"1977","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/922890","citation_count":200,"is_preprint":false},{"pmid":"26884068","id":"PMC_26884068","title":"The role of APOE in cerebrovascular dysfunction.","date":"2016","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/26884068","citation_count":195,"is_preprint":false},{"pmid":"27386935","id":"PMC_27386935","title":"Do the Apoe-/- and Ldlr-/- Mice Yield the Same Insight on Atherogenesis?","date":"2016","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27386935","citation_count":160,"is_preprint":false},{"pmid":"38906999","id":"PMC_38906999","title":"Multifaceted roles of APOE in Alzheimer disease.","date":"2024","source":"Nature reviews. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/38906999","citation_count":137,"is_preprint":false},{"pmid":"10436064","id":"PMC_10436064","title":"Truncated apolipoprotein E (ApoE) causes increased intracellular calcium and may mediate ApoE neurotoxicity.","date":"1999","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/10436064","citation_count":133,"is_preprint":false},{"pmid":"28057414","id":"PMC_28057414","title":"ApoE, ApoE Receptors, and the Synapse in Alzheimer's Disease.","date":"2017","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/28057414","citation_count":129,"is_preprint":false},{"pmid":"19174369","id":"PMC_19174369","title":"Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice.","date":"2009","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/19174369","citation_count":125,"is_preprint":false},{"pmid":"31938053","id":"PMC_31938053","title":"Formononetin attenuates atherosclerosis via regulating interaction between KLF4 and SRA in apoE-/- mice.","date":"2020","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/31938053","citation_count":116,"is_preprint":false},{"pmid":"31911114","id":"PMC_31911114","title":"APOE in the normal brain.","date":"2020","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/31911114","citation_count":113,"is_preprint":false},{"pmid":"11597927","id":"PMC_11597927","title":"Lipoprotein size and atherosclerosis susceptibility in Apoe(-/-) and Ldlr(-/-) mice.","date":"2001","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11597927","citation_count":112,"is_preprint":false},{"pmid":"14754908","id":"PMC_14754908","title":"Molecular interactions between apoE and ABCA1: impact on apoE lipidation.","date":"2004","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/14754908","citation_count":110,"is_preprint":false},{"pmid":"26980204","id":"PMC_26980204","title":"Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.","date":"2016","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/26980204","citation_count":95,"is_preprint":false},{"pmid":"18185033","id":"PMC_18185033","title":"APOE, APOE promoter, and Tau genotypes and risk for concussion in college athletes.","date":"2008","source":"Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18185033","citation_count":93,"is_preprint":false},{"pmid":"23560095","id":"PMC_23560095","title":"BAFF receptor mAb treatment ameliorates development and progression of atherosclerosis in hyperlipidemic ApoE(-/-) mice.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23560095","citation_count":88,"is_preprint":false},{"pmid":"8892881","id":"PMC_8892881","title":"Comparative analysis of adenovirus fiber-cell interaction: adenovirus type 2 (Ad2) and Ad9 utilize the same cellular fiber receptor but use different binding strategies for attachment.","date":"1996","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/8892881","citation_count":87,"is_preprint":false},{"pmid":"37117743","id":"PMC_37117743","title":"Destabilizing heterochromatin by APOE mediates senescence.","date":"2022","source":"Nature aging","url":"https://pubmed.ncbi.nlm.nih.gov/37117743","citation_count":85,"is_preprint":false},{"pmid":"29510138","id":"PMC_29510138","title":"AIM2 accelerates the atherosclerotic plaque progressions in ApoE-/- mice.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29510138","citation_count":81,"is_preprint":false},{"pmid":"20854809","id":"PMC_20854809","title":"Tanshinone IIA attenuates atherosclerosis in ApoE(-/-) mice through down-regulation of scavenger receptor expression.","date":"2010","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20854809","citation_count":77,"is_preprint":false},{"pmid":"30232753","id":"PMC_30232753","title":"ApoE and Neurodegenerative Diseases in Aging.","date":"2018","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/30232753","citation_count":71,"is_preprint":false},{"pmid":"15708438","id":"PMC_15708438","title":"apoE isoforms and measures of anxiety in probable AD patients and Apoe-/- mice.","date":"2005","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/15708438","citation_count":70,"is_preprint":false},{"pmid":"26169727","id":"PMC_26169727","title":"Endothelial NADPH oxidase 4 protects ApoE-/- mice from atherosclerotic lesions.","date":"2015","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26169727","citation_count":68,"is_preprint":false},{"pmid":"39532095","id":"PMC_39532095","title":"Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes.","date":"2024","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/39532095","citation_count":65,"is_preprint":false},{"pmid":"25784693","id":"PMC_25784693","title":"IL-9 aggravates the development of atherosclerosis in ApoE-/- mice.","date":"2015","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/25784693","citation_count":64,"is_preprint":false},{"pmid":"22959484","id":"PMC_22959484","title":"Local heart irradiation of ApoE(-/-) mice induces microvascular and endocardial damage and accelerates coronary atherosclerosis.","date":"2012","source":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22959484","citation_count":63,"is_preprint":false},{"pmid":"23112842","id":"PMC_23112842","title":"The apolipoprotein E (APOE) gene appears functionally monomorphic in chimpanzees (Pan troglodytes).","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23112842","citation_count":62,"is_preprint":false},{"pmid":"12192621","id":"PMC_12192621","title":"APOE-epsilon4 and APOE -491A polymorphisms in individuals with subjective memory loss.","date":"2002","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/12192621","citation_count":59,"is_preprint":false},{"pmid":"20693162","id":"PMC_20693162","title":"Mast cell chymase inhibition reduces atherosclerotic plaque progression and improves plaque stability in ApoE-/- mice.","date":"2010","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/20693162","citation_count":59,"is_preprint":false},{"pmid":"36888629","id":"PMC_36888629","title":"Butyrate suppresses atherosclerotic inflammation by regulating macrophages and polarization via GPR43/HDAC-miRNAs axis in ApoE-/- mice.","date":"2023","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/36888629","citation_count":59,"is_preprint":false},{"pmid":"169392","id":"PMC_169392","title":"Adenovirus transcription. II. RNA sequences complementary to simian virus 40 and adenovirus 2DNA in AD2+ND1- and AD2+ND3-infected cells.","date":"1975","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/169392","citation_count":54,"is_preprint":false},{"pmid":"24991786","id":"PMC_24991786","title":"Baicalin and geniposide attenuate atherosclerosis involving lipids regulation and immunoregulation in ApoE-/- mice.","date":"2014","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24991786","citation_count":54,"is_preprint":false},{"pmid":"26606905","id":"PMC_26606905","title":"High-methionine diets accelerate atherosclerosis by HHcy-mediated FABP4 gene demethylation pathway via DNMT1 in ApoE(-/-) mice.","date":"2015","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/26606905","citation_count":54,"is_preprint":false},{"pmid":"28473446","id":"PMC_28473446","title":"Human Plasma Thioredoxin-80 Increases With Age and in ApoE-/- Mice Induces Inflammation, Angiogenesis, and Atherosclerosis.","date":"2017","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/28473446","citation_count":53,"is_preprint":false},{"pmid":"1846134","id":"PMC_1846134","title":"Purification and characterization of haloalcohol dehalogenase from Arthrobacter sp. strain AD2.","date":"1991","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/1846134","citation_count":53,"is_preprint":false},{"pmid":"10669641","id":"PMC_10669641","title":"Complete atherosclerosis regression after human ApoE gene transfer in ApoE-deficient/nude mice.","date":"2000","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10669641","citation_count":52,"is_preprint":false},{"pmid":"30630636","id":"PMC_30630636","title":"Geniposide regulates the miR-101/MKP-1/p38 pathway and alleviates atherosclerosis inflammatory injury in ApoE-/- mice.","date":"2018","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/30630636","citation_count":51,"is_preprint":false},{"pmid":"33241629","id":"PMC_33241629","title":"Acacetin exerts antioxidant potential against atherosclerosis through Nrf2 pathway in apoE-/- Mice.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33241629","citation_count":51,"is_preprint":false},{"pmid":"33397400","id":"PMC_33397400","title":"Identification of epigenome-wide DNA methylation differences between carriers of APOE ε4 and APOE ε2 alleles.","date":"2021","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33397400","citation_count":50,"is_preprint":false},{"pmid":"38870781","id":"PMC_38870781","title":"Activation of Nrf2 inhibits atherosclerosis in ApoE-/- mice through suppressing endothelial cell inflammation and lipid peroxidation.","date":"2024","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/38870781","citation_count":45,"is_preprint":false},{"pmid":"32086626","id":"PMC_32086626","title":"Inhibition of JAK2 Suppresses Myelopoiesis and Atherosclerosis in Apoe-/- Mice.","date":"2020","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32086626","citation_count":44,"is_preprint":false},{"pmid":"31606534","id":"PMC_31606534","title":"Inflammation inhibition and gut microbiota regulation by TSG to combat atherosclerosis in ApoE-/- mice.","date":"2019","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31606534","citation_count":43,"is_preprint":false},{"pmid":"29745836","id":"PMC_29745836","title":"Haplotype analysis of APOE intragenic SNPs.","date":"2018","source":"BMC neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/29745836","citation_count":42,"is_preprint":false},{"pmid":"23603214","id":"PMC_23603214","title":"Mercury, APOE, and children's neurodevelopment.","date":"2013","source":"Neurotoxicology","url":"https://pubmed.ncbi.nlm.nih.gov/23603214","citation_count":41,"is_preprint":false},{"pmid":"33327743","id":"PMC_33327743","title":"TSP-1 (Thrombospondin-1) Deficiency Protects ApoE-/- Mice Against Leptin-Induced Atherosclerosis.","date":"2020","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/33327743","citation_count":40,"is_preprint":false},{"pmid":"22482072","id":"PMC_22482072","title":"Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics.","date":"2012","source":"International journal of Alzheimer's disease","url":"https://pubmed.ncbi.nlm.nih.gov/22482072","citation_count":40,"is_preprint":false},{"pmid":"22221592","id":"PMC_22221592","title":"Apolipoprotein E gene (APOE) genotype in Wilson's disease: impact on clinical presentation.","date":"2012","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/22221592","citation_count":40,"is_preprint":false},{"pmid":"38614985","id":"PMC_38614985","title":"Targeted delivery of MerTK protein via cell membrane engineered nanoparticle enhances efferocytosis and attenuates atherosclerosis in diabetic ApoE-/- Mice.","date":"2024","source":"Journal of nanobiotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/38614985","citation_count":39,"is_preprint":false},{"pmid":"29135917","id":"PMC_29135917","title":"Asperlin Inhibits LPS-Evoked Foam Cell Formation and Prevents Atherosclerosis in ApoE-/- Mice.","date":"2017","source":"Marine drugs","url":"https://pubmed.ncbi.nlm.nih.gov/29135917","citation_count":38,"is_preprint":false},{"pmid":"28086184","id":"PMC_28086184","title":"Sex and APOE: A memory advantage in male APOE ε4 carriers in midlife.","date":"2016","source":"Cortex; a journal devoted to the study of the nervous system and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/28086184","citation_count":38,"is_preprint":false},{"pmid":"90174","id":"PMC_90174","title":"Cell surface location of simian virus 40-specific proteins on HeLa cells infected with adenovirus type 2-simian virus 40 hybrid viruses Ad2+ND1 and Ad2+ND2.","date":"1979","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/90174","citation_count":38,"is_preprint":false},{"pmid":"34725437","id":"PMC_34725437","title":"FABP4 activates the JAK2/STAT2 pathway via Rap1a in the homocysteine-induced macrophage inflammatory response in ApoE-/- mice atherosclerosis.","date":"2021","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34725437","citation_count":38,"is_preprint":false},{"pmid":"21477221","id":"PMC_21477221","title":"Npp1 promotes atherosclerosis in ApoE knockout mice.","date":"2011","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21477221","citation_count":36,"is_preprint":false},{"pmid":"33381046","id":"PMC_33381046","title":"Astragalus Flavone Ameliorates Atherosclerosis and Hepatic Steatosis Via Inhibiting Lipid-Disorder and Inflammation in apoE-/- Mice.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33381046","citation_count":34,"is_preprint":false},{"pmid":"15246985","id":"PMC_15246985","title":"The role of viruses and of APOE in dementia.","date":"2004","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15246985","citation_count":33,"is_preprint":false},{"pmid":"29292046","id":"PMC_29292046","title":"Celosins inhibit atherosclerosis in ApoE-/- mice and promote autophagy flow.","date":"2017","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29292046","citation_count":33,"is_preprint":false},{"pmid":"24115173","id":"PMC_24115173","title":"Concerning the structure of apoE.","date":"2013","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/24115173","citation_count":33,"is_preprint":false},{"pmid":"22662117","id":"PMC_22662117","title":"Ginkgolide B reduces atherogenesis and vascular inflammation in ApoE(-/-) mice.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22662117","citation_count":33,"is_preprint":false},{"pmid":"9742120","id":"PMC_9742120","title":"The AD1 and AD2 transactivation domains of E2A are essential for the antiapoptotic activity of the chimeric oncoprotein E2A-HLF.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9742120","citation_count":32,"is_preprint":false},{"pmid":"17234687","id":"PMC_17234687","title":"Oxidatively damaged DNA in aging dyslipidemic ApoE-/- and wild-type mice.","date":"2007","source":"Mutagenesis","url":"https://pubmed.ncbi.nlm.nih.gov/17234687","citation_count":32,"is_preprint":false},{"pmid":"32047914","id":"PMC_32047914","title":"Protocatechuic Acid Inhibits Vulnerable Atherosclerotic Lesion Progression in Older Apoe-/- Mice.","date":"2020","source":"The Journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/32047914","citation_count":31,"is_preprint":false},{"pmid":"30909226","id":"PMC_30909226","title":"Metformin Therapy Aggravates Neurodegenerative Processes in ApoE-/- Mice.","date":"2019","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/30909226","citation_count":31,"is_preprint":false},{"pmid":"37171075","id":"PMC_37171075","title":"APOE expression and secretion are modulated by mitochondrial dysfunction.","date":"2023","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/37171075","citation_count":30,"is_preprint":false},{"pmid":"35115575","id":"PMC_35115575","title":"APOE genetics influence murine gut microbiome.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35115575","citation_count":30,"is_preprint":false},{"pmid":"30947667","id":"PMC_30947667","title":"Tanshinone IIA Promotes Macrophage Cholesterol Efflux and Attenuates Atherosclerosis of apoE-/- Mice by Omentin-1/ABCA1 Pathway.","date":"2019","source":"Current pharmaceutical biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/30947667","citation_count":30,"is_preprint":false},{"pmid":"23017835","id":"PMC_23017835","title":"The comprehensive effects of hyperlipidemia and hyperhomocysteinemia on pathogenesis of atherosclerosis and DNA hypomethylation in ApoE-/- mice.","date":"2012","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/23017835","citation_count":30,"is_preprint":false},{"pmid":"39031528","id":"PMC_39031528","title":"Advancements in APOE and dementia research: Highlights from the 2023 AAIC Advancements: APOE conference.","date":"2024","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/39031528","citation_count":28,"is_preprint":false},{"pmid":"36975090","id":"PMC_36975090","title":"APOE and immunity: Research highlights.","date":"2023","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/36975090","citation_count":27,"is_preprint":false},{"pmid":"17244188","id":"PMC_17244188","title":"The missing ApoE allele.","date":"2007","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17244188","citation_count":26,"is_preprint":false},{"pmid":"21196212","id":"PMC_21196212","title":"The neurobiology of APOE in schizophrenia and mood disorders.","date":"2011","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/21196212","citation_count":25,"is_preprint":false},{"pmid":"31781638","id":"PMC_31781638","title":"Adipokine Chemerin Stimulates Progression of Atherosclerosis in ApoE-/- Mice.","date":"2019","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/31781638","citation_count":25,"is_preprint":false},{"pmid":"29075339","id":"PMC_29075339","title":"Berberine ameliorates non-alcoholic steatohepatitis in ApoE-/- mice.","date":"2017","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29075339","citation_count":25,"is_preprint":false},{"pmid":"22859494","id":"PMC_22859494","title":"The methyl xanthine caffeine inhibits DNA damage signaling and reactive species and reduces atherosclerosis in ApoE(-/-) mice.","date":"2012","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22859494","citation_count":25,"is_preprint":false},{"pmid":"37051929","id":"PMC_37051929","title":"Contribution of APOE Genetic Variants to Dyslipidemia.","date":"2023","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/37051929","citation_count":23,"is_preprint":false},{"pmid":"32739681","id":"PMC_32739681","title":"Angiopoietin-like protein 8 accelerates atherosclerosis in ApoE-/- mice.","date":"2020","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/32739681","citation_count":23,"is_preprint":false},{"pmid":"36055579","id":"PMC_36055579","title":"Genetic disruption of the Gipr in Apoe-/- mice promotes atherosclerosis.","date":"2022","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/36055579","citation_count":23,"is_preprint":false},{"pmid":"33991749","id":"PMC_33991749","title":"Myeloid cell-specific Irf5 deficiency stabilizes atherosclerotic plaques in Apoe-/- mice.","date":"2021","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33991749","citation_count":23,"is_preprint":false},{"pmid":"178903","id":"PMC_178903","title":"Simian virus 40-specific polypeptides in AD2+ ND1- and Ad2+ ND4-infected cells.","date":"1976","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/178903","citation_count":23,"is_preprint":false},{"pmid":"10949525","id":"PMC_10949525","title":"Apolipoprotein E (APOE) phenotype and APOE concentrations in multiple sclerosis and acute herpes zoster.","date":"2000","source":"Acta neurologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/10949525","citation_count":23,"is_preprint":false},{"pmid":"34552216","id":"PMC_34552216","title":"Antiatherosclerotic effect of dehydrocorydaline on ApoE-/- mice: inhibition of macrophage inflammation.","date":"2021","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/34552216","citation_count":23,"is_preprint":false},{"pmid":"29729306","id":"PMC_29729306","title":"Postnatal chlorpyrifos exposure and apolipoprotein E (APOE) genotype differentially affect cholinergic expression and developmental parameters in transgenic mice.","date":"2018","source":"Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association","url":"https://pubmed.ncbi.nlm.nih.gov/29729306","citation_count":23,"is_preprint":false},{"pmid":"18415033","id":"PMC_18415033","title":"Regulated proteolysis of APP and ApoE receptors.","date":"2008","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/18415033","citation_count":22,"is_preprint":false},{"pmid":"27856455","id":"PMC_27856455","title":"Map3k8 Modulates Monocyte State and Atherogenesis in ApoE-/- Mice.","date":"2016","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27856455","citation_count":22,"is_preprint":false},{"pmid":"26051858","id":"PMC_26051858","title":"The leukotriene B4 receptor (BLT) antagonist BIIL284 decreases atherosclerosis in ApoE-/- mice.","date":"2015","source":"Prostaglandins & other lipid mediators","url":"https://pubmed.ncbi.nlm.nih.gov/26051858","citation_count":22,"is_preprint":false},{"pmid":"34428895","id":"PMC_34428895","title":"Lycopene Reduces Cholesterol Absorption and Prevents Atherosclerosis in ApoE-/- Mice by Downregulating HNF-1α and NPC1L1 Expression.","date":"2021","source":"Journal of agricultural and food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34428895","citation_count":22,"is_preprint":false},{"pmid":"26649902","id":"PMC_26649902","title":"SAP deficiency mitigated atherosclerotic lesions in ApoE(-/-) mice.","date":"2015","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/26649902","citation_count":21,"is_preprint":false},{"pmid":"25843117","id":"PMC_25843117","title":"Chitosan Oligosaccharides Attenuate Atherosclerosis and Decrease Non-HDL in ApoE-/- Mice.","date":"2015","source":"Journal of atherosclerosis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/25843117","citation_count":21,"is_preprint":false},{"pmid":"32919187","id":"PMC_32919187","title":"Downregulation of G3BP2 reduces atherosclerotic lesions in ApoE-/- mice.","date":"2020","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/32919187","citation_count":21,"is_preprint":false},{"pmid":"18164902","id":"PMC_18164902","title":"Analyses of variants located in estrogen metabolism genes (ESR1, ESR2, COMT and APOE) and schizophrenia.","date":"2007","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/18164902","citation_count":21,"is_preprint":false},{"pmid":"38132357","id":"PMC_38132357","title":"The Impact of Apolipoprotein E (APOE) Epigenetics on Aging and Sporadic Alzheimer's Disease.","date":"2023","source":"Biology","url":"https://pubmed.ncbi.nlm.nih.gov/38132357","citation_count":20,"is_preprint":false},{"pmid":"32091078","id":"PMC_32091078","title":"Myriocin and d-PDMP ameliorate atherosclerosis in ApoE-/- mice via reducing lipid uptake and vascular inflammation.","date":"2020","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/32091078","citation_count":20,"is_preprint":false},{"pmid":"19058878","id":"PMC_19058878","title":"Amyloid precursor protein mediates monocyte adhesion in AD tissue and apoE(-)/(-) mice.","date":"2008","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/19058878","citation_count":20,"is_preprint":false},{"pmid":"34954030","id":"PMC_34954030","title":"Pharmacological inhibition of IRAK1 and IRAK4 prevents endothelial inflammation and atherosclerosis in ApoE-/- mice.","date":"2021","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/34954030","citation_count":19,"is_preprint":false},{"pmid":"30912221","id":"PMC_30912221","title":"Immunohistochemical biomarkers and distribution of telocytes in ApoE-/- mice.","date":"2019","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/30912221","citation_count":19,"is_preprint":false},{"pmid":"27831589","id":"PMC_27831589","title":"The anti-inflammatory vasostatin-2 attenuates atherosclerosis in ApoE-/- mice and inhibits monocyte/macrophage recruitment.","date":"2016","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/27831589","citation_count":19,"is_preprint":false},{"pmid":"27237075","id":"PMC_27237075","title":"TRAF3IP2 mediates atherosclerotic plaque development and vulnerability in ApoE(-/-) mice.","date":"2016","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/27237075","citation_count":18,"is_preprint":false},{"pmid":"32967121","id":"PMC_32967121","title":"Plasma APE1/Ref-1 Correlates with Atherosclerotic Inflammation in ApoE-/- Mice.","date":"2020","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/32967121","citation_count":18,"is_preprint":false},{"pmid":"26005211","id":"PMC_26005211","title":"The association of apolipoprotein E (APOE) gene polymorphisms with atherosclerosis susceptibility: a meta-analysis.","date":"2015","source":"Minerva cardioangiologica","url":"https://pubmed.ncbi.nlm.nih.gov/26005211","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54213,"output_tokens":3848,"usd":0.110179,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11717,"output_tokens":4462,"usd":0.085068,"stage2_stop_reason":"end_turn"},"total_usd":0.195247,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"ApoE facilitates the proteolytic clearance of soluble Aβ from the brain: endolytic degradation of Aβ within microglia by neprilysin is dramatically enhanced by ApoE, and extracellular Aβ degradation by insulin-degrading enzyme is also facilitated by ApoE. This capacity depends on ApoE isoform and lipidation status. Activation of liver X receptors (LXR) increases lipidated ApoE and stimulates Aβ degradation in vivo.\",\n      \"method\": \"In vitro degradation assays with microglia and purified enzymes; LXR agonist treatment of Tg2576 mice with measurement of brain Aβ load and contextual memory\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal in vitro and in vivo methods, replicated across enzyme systems and cellular contexts in a single rigorous study\",\n      \"pmids\": [\"18549781\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ApoE does not directly bind soluble Aβ to an appreciable extent in solution or in human CSF. Instead, apoE regulates soluble Aβ metabolism by competing with Aβ for LRP1-dependent cellular uptake in astrocytes, thereby modulating Aβ clearance without requiring direct apoE–Aβ complex formation in extracellular fluids.\",\n      \"method\": \"Multiple biochemical and analytical techniques (SEC, native PAGE, SPR); brain Aβ microdialysis in mice receiving apoE infusions; LRP1 competition assays in astrocytes\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal biochemical methods plus in vivo microdialysis; rigorous negative result on direct binding and positive mechanistic result on LRP1 competition\",\n      \"pmids\": [\"23620513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ApoE3, but not ApoE4, protects against excitotoxin-induced and age-dependent neurodegeneration in mouse brain. Expression of human apoE3 in Apoe-/- mice preserved synaptophysin-positive presynaptic terminals, MAP2-positive dendrites, and neurofilament-positive axons after kainic acid challenge, whereas apoE4 did not.\",\n      \"method\": \"Neuron-specific enolase promoter-driven expression of human apoE3 or apoE4 in Apoe-/- mice; kainic acid challenge; immunohistochemical quantification of synaptic and dendritic markers\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic rescue experiment in defined knockout background with multiple immunohistochemical readouts, isoform-specific phenotype\",\n      \"pmids\": [\"10366621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"All human ApoE isoforms directly inhibit the classical complement cascade (CCC) by binding with high affinity (KD ~140–580 pM) to activated C1q, forming ApoE–C1q complexes. In ApoE-deficient mice, oxidized lipids activate the CCC, causing leukocyte infiltration; ApoE suppresses this by acting as a direct checkpoint inhibitor of complement activation.\",\n      \"method\": \"In vitro binding assays (SPR/biophysical measurement of KD); immunostaining of C1q-ApoE complexes in human and mouse tissue; siRNA knockdown of C5 in mice; analysis of ApoE-/- mouse choroid plexus inflammation\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct binding measured with KD determination, multiple in vivo models, human tissue validation, orthogonal siRNA intervention\",\n      \"pmids\": [\"30692699\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Truncated ApoE (22 kDa N-terminal fragment) and ApoE-derived peptides cause neurotoxicity and increases in intracellular calcium in embryonic rat hippocampal neurons. The calcium influx and cell death are reduced by receptor-associated protein (RAP), removal of extracellular calcium, or the NMDA receptor antagonist MK-801, indicating involvement of cell-surface receptors including NMDA receptors.\",\n      \"method\": \"Primary embryonic rat hippocampal neuron culture; intracellular calcium imaging; pharmacological inhibition with RAP and MK-801; protease inhibitor experiments\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological tools in primary neurons, single lab, no structural or reconstitution confirmation\",\n      \"pmids\": [\"10436064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ApoE3 forms a direct complex with ABCA1 on the surface of intact fibroblasts. Lipid-free apoE3 competes with apoA-I for ABCA1 binding and promotes ABCA1-dependent cholesterol efflux. This interaction generates nascent apoE/cholesterol/phospholipid particles of 9–15 nm with prebeta electrophoretic mobility. A Tangier disease mutation in ABCA1 (C1477R) abolishes both apoE3 binding and apoE3-mediated cholesterol efflux, demonstrating that ABCA1 is essential for biogenesis of apoE-containing HDL-sized particles.\",\n      \"method\": \"125I-apoA-I competition binding assays; cholesterol efflux assays with ABCA1 mutant cells; native PAGE sizing of nascent particles; stimulated intact human fibroblasts\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct binding competition, functional efflux assay, mutant-rescue design, particle characterization by PAGE; multiple orthogonal methods in single study\",\n      \"pmids\": [\"14754908\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"APOE accumulation in aged human mesenchymal progenitor cells (MPCs) drives cellular senescence by destabilizing heterochromatin. Mechanistically, increased APOE causes autophagy-lysosomal pathway-dependent degradation of nuclear lamina proteins and the heterochromatin-associated protein KAP1 (KRAB-associated protein 1), thereby disrupting heterochromatin organization. CRISPR-Cas9 deletion of APOE confers resistance to senescence in human MPCs.\",\n      \"method\": \"CRISPR-Cas9 knockout of APOE in human MPCs; stress-induced and physiological aging models; immunoblot and immunofluorescence for lamin and KAP1; autophagy-lysosome pathway inhibition experiments\",\n      \"journal\": \"Nature aging\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic CRISPR deletion with defined molecular mechanism (autophagy-lysosomal degradation of heterochromatin proteins), multiple cell models and orthogonal methods\",\n      \"pmids\": [\"37117743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Lipidated ApoE2 (lipApoE2) has impaired binding to the LDL receptor (LDLR) compared with lipApoE3/4, which avoids LDLR recycling defects and reduces uptake of cholesteryl esters (CEs) into neurons. In human neurons, ApoE carrying polyunsaturated fatty acid-CE (PUFA-CE) causes lysosomal lipofuscinosis in an allelic series (ApoE4 > ApoE3 > ApoE2); lipofuscin accumulation promotes lysosomal retention of tau fibrils. The protective Christchurch mutation also reduces LDLR binding and phenocopies ApoE2. Intrahippocampal injection of PUFA-CE-lipApoE4 alone is sufficient to induce lipofuscinosis in wild-type mice.\",\n      \"method\": \"iPSC-derived human neurons; LDLR binding assays; cholesteryl ester uptake measurements; lipofuscin quantification; tau fibril lysosomal assay; intrahippocampal injection in mice; 5xFAD mouse brain analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — reconstitution in human neurons with isoform series, in vivo injection sufficiency experiment, mutant (Christchurch) phenocopy, multiple orthogonal assays in one rigorous study\",\n      \"pmids\": [\"39532095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Mitochondrial dysfunction (genetic disruption of SLC25A transporters or pharmacological/genetic inhibition of electron transport chain complexes I, III, or IV) causes upregulation of APOE transcript, protein, and secretion (up to 49-fold) in diverse cell types including iPSC-derived human astrocytes, as part of an inflammatory gene expression program. Age- and genotype-dependent decline in respiratory complex I preceded increased APOE in the 5xFAD mouse brain.\",\n      \"method\": \"Gene editing of SLC25A transporters; pharmacological ETC inhibition; iPSC-derived astrocytes; qRT-PCR and ELISA for APOE; 5xFAD mouse brain immunoblots\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic and pharmacological perturbations in multiple cell types, single lab, no direct mechanistic link elucidated between ETC and APOE transcription\",\n      \"pmids\": [\"37171075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The structure of full-length apoE3 (two-domain protein, 34 kDa) was determined and showed that mutations in the N-terminal domain can be propagated through the structure to the C-terminal domain. The single amino acid difference between apoE3 and apoE4 underlies structural differences relevant to their distinct disease-related functions.\",\n      \"method\": \"Review/analysis of 2011 structure determination; structural interpretation of isoform differences\",\n      \"journal\": \"Protein science : a publication of the Protein Society\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — this abstract is a review/perspective that references a 2011 structure paper without presenting new experimental data; structural claim cannot be directly verified from this abstract\",\n      \"pmids\": [\"24115173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ApoE variants affecting VLDL binding affinity to the LDL receptor were directly assayed in vitro. Variants p.(Arg163Cys) and p.(Arg165Trp) showed intermediate LDLR affinity between APOE2/2 and APOE3/3, while p.(Gly145Asp) and p.(Pro220Leu) showed higher affinity than APOE3/3, demonstrating that specific APOE coding variants alter receptor-binding function and contribute to dysbetalipoproteinemia.\",\n      \"method\": \"In vitro VLDL-to-LDLR binding affinity assay with patient-derived variants; NMR lipoprotein particle analysis\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct in vitro receptor binding assay with functional implication, but single lab and limited mechanistic follow-up\",\n      \"pmids\": [\"37051929\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PCSK9 increases hepatic lipid and lipoprotein production via mechanisms dependent on both LDLR and apoE. In transgenic mice expressing human PCSK9 on an apoE-null background, the lipid-raising effect of PCSK9 is abolished, demonstrating that apoE is required for PCSK9-mediated hepatic lipogenesis and dyslipidemia.\",\n      \"method\": \"Transgenic hPCSK9 mice on WT, LDLR-/-, and apoE-/- backgrounds; plasma lipid measurement; hepatic gene expression analysis\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis using defined knockout backgrounds, multiple lipid and gene expression readouts, single lab\",\n      \"pmids\": [\"26980204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Somatic gene transfer of human APOE cDNA via adenoviral vector into ApoE-deficient nude mice restored plasma apoE secretion, normalized hypercholesterolemia within 14 days, and induced dose-dependent regression of pre-existing fatty streak lesions in the aorta, demonstrating that apoE expression is sufficient to reverse atherosclerotic lesions.\",\n      \"method\": \"Adenoviral gene transfer into ApoE-/- nude mice; plasma cholesterol and triglyceride measurement; aortic lesion quantification\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic rescue experiment with defined functional outcome (lesion regression), single lab\",\n      \"pmids\": [\"10669641\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ApoE is a secreted lipid transport protein that facilitates Aβ clearance through LRP1-dependent pathways and protease-mediated degradation in the brain, directly inhibits classical complement activation via high-affinity C1q binding, promotes cholesterol efflux through ABCA1 interaction and lipidated-particle formation, regulates neuronal cholesterol/lipid uptake via LDLR with isoform-dependent pathogenicity (ApoE4 > ApoE3 > ApoE2), drives cellular senescence by destabilizing heterochromatin through autophagy-lysosomal degradation of lamin and KAP1, and is transcriptionally upregulated as part of an inflammatory program downstream of mitochondrial dysfunction; isoform-specific differences in receptor binding, lipidation, and structural domain communication underlie the differential risk of Alzheimer's disease and cardiovascular disease conferred by the ε2, ε3, and ε4 alleles.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ApoE is a secreted, two-domain lipid transport protein that governs cholesterol and lipoprotein trafficking in the periphery and brain, with allele-specific structural differences (ε2/ε3/ε4) translating into differential disease risk [#9]. In lipid handling, lipid-free ApoE3 binds ABCA1 directly, competes with apoA-I, and drives ABCA1-dependent cholesterol efflux to form nascent 9–15 nm prebeta HDL-sized particles [#5], while lipidated ApoE engages the LDL receptor in an isoform-graded manner that controls neuronal cholesteryl-ester uptake; impaired LDLR binding by ApoE2 and the Christchurch mutation reduces uptake and is protective, whereas ApoE4 promotes lysosomal lipofuscinosis and retention of tau fibrils (ApoE4 > ApoE3 > ApoE2) [#7]. In Aβ metabolism, ApoE does not appreciably bind soluble Aβ directly but instead competes with Aβ for LRP1-dependent cellular uptake in astrocytes [#1] and enhances proteolytic Aβ degradation by neprilysin and insulin-degrading enzyme in a lipidation-dependent manner stimulated by LXR activation [#0]. ApoE also acts as a high-affinity checkpoint inhibitor of the classical complement cascade by binding activated C1q (KD ~140–580 pM), suppressing complement-driven leukocyte infiltration [#3], and ApoE3 (but not ApoE4) preserves synaptic, dendritic, and axonal integrity against excitotoxic neurodegeneration [#2]. In aged mesenchymal progenitor cells, APOE accumulation drives cellular senescence by promoting autophagy-lysosomal degradation of nuclear lamina proteins and KAP1, destabilizing heterochromatin [#6], and APOE is transcriptionally upregulated as part of an inflammatory program downstream of mitochondrial/electron-transport-chain dysfunction [#8]. Peripherally, ApoE expression is sufficient to reverse hypercholesterolemia and atherosclerotic lesions in ApoE-deficient mice [#12], is required for PCSK9-mediated hepatic lipogenesis [#11], and specific coding variants alter LDLR binding affinity and contribute to dysbetalipoproteinemia [#10].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established that ApoE protects against neurodegeneration in an isoform-specific manner, framing ApoE3 as neuroprotective and ApoE4 as deficient in this protection.\",\n      \"evidence\": \"Neuron-specific expression of human apoE3 or apoE4 in Apoe-/- mice with kainic acid challenge and immunohistochemical quantification of synaptic/dendritic/axonal markers\",\n      \"pmids\": [\"10366621\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of ApoE3 neuroprotection not defined\", \"Does not connect protection to a specific receptor or lipid pathway\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Showed that truncated ApoE fragments are directly neurotoxic via receptor- and calcium-dependent mechanisms, implicating ApoE proteolysis in neuronal injury.\",\n      \"evidence\": \"Primary embryonic rat hippocampal neuron culture with calcium imaging and pharmacological inhibition (RAP, MK-801)\",\n      \"pmids\": [\"10436064\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab without structural or reconstitution confirmation\", \"Identity of the cell-surface receptor mediating toxicity not pinned down\", \"Relevance of fragment generation in vivo unclear\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrated that ApoE expression is sufficient not only to correct hypercholesterolemia but to reverse pre-existing atherosclerotic lesions, establishing causal sufficiency for vascular protection.\",\n      \"evidence\": \"Adenoviral APOE gene transfer into ApoE-/- nude mice with plasma lipid and aortic lesion quantification\",\n      \"pmids\": [\"10669641\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Does not isolate which ApoE function (clearance vs efflux) drives regression\", \"No isoform comparison\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified ABCA1 as a direct ApoE3 binding partner mediating cholesterol efflux and biogenesis of nascent ApoE-HDL particles, linking ApoE to reverse cholesterol transport machinery.\",\n      \"evidence\": \"125I-apoA-I competition binding, cholesterol efflux assays in ABCA1 mutant (Tangier C1477R) fibroblasts, and native PAGE particle sizing\",\n      \"pmids\": [\"14754908\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Isoform dependence of ABCA1 binding not fully resolved\", \"Structural basis of ApoE-ABCA1 interaction unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Established that ApoE facilitates proteolytic Aβ clearance in a lipidation-dependent manner, connecting ApoE lipid state and LXR signaling to amyloid degradation.\",\n      \"evidence\": \"In vitro degradation assays with microglia/purified neprilysin and IDE, plus LXR agonist treatment of Tg2576 mice with brain Aβ and memory readouts\",\n      \"pmids\": [\"18549781\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative isoform contributions to clearance not separated\", \"Whether effect is direct enzyme modulation or substrate presentation unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Resolved the mechanism of ApoE-Aβ interaction by showing ApoE does not bind soluble Aβ directly but competes for LRP1-mediated uptake, reframing ApoE as a clearance modulator rather than an Aβ chaperone.\",\n      \"evidence\": \"SEC, native PAGE, SPR biochemistry plus in vivo brain Aβ microdialysis and astrocyte LRP1 competition assays\",\n      \"pmids\": [\"23620513\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Isoform differences in LRP1 competition not quantified here\", \"Relationship to proteolytic clearance pathway not integrated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Provided the structural rationale for isoform effects by showing the full-length two-domain ApoE3 structure propagates N-terminal mutations to the C-terminal domain.\",\n      \"evidence\": \"Review/analysis of a prior structure determination of full-length apoE3\",\n      \"pmids\": [\"24115173\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Review/perspective without new experimental data; structural claim not directly verifiable from this source\", \"No direct functional mapping of domain communication to receptor binding\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Placed ApoE genetically downstream of PCSK9 by showing ApoE is required for PCSK9-driven hepatic lipogenesis, defining an ApoE-dependent arm of dyslipidemia.\",\n      \"evidence\": \"Transgenic hPCSK9 mice on WT, LDLR-/-, and apoE-/- backgrounds with plasma lipid and hepatic expression analysis\",\n      \"pmids\": [\"26980204\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which ApoE enables PCSK9-driven lipogenesis not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed a non-lipid function of ApoE as a high-affinity inhibitor of the classical complement cascade through direct C1q binding, establishing ApoE as a complement checkpoint.\",\n      \"evidence\": \"SPR KD determination, C1q-ApoE complex immunostaining in human/mouse tissue, C5 siRNA knockdown, and ApoE-/- choroid plexus inflammation analysis\",\n      \"pmids\": [\"30692699\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Isoform-specific differences in C1q inhibition not delineated\", \"Structural basis of ApoE-C1q binding unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Uncovered a cell-intrinsic pro-senescence role for APOE, showing its accumulation destabilizes heterochromatin via autophagy-lysosomal degradation of lamin and KAP1.\",\n      \"evidence\": \"CRISPR-Cas9 APOE knockout in human MPCs, aging/stress models, immunoblot/immunofluorescence for lamin and KAP1, and autophagy-lysosome inhibition\",\n      \"pmids\": [\"37117743\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How secreted/intracellular APOE triggers lysosomal targeting of nuclear proteins is unclear\", \"Isoform dependence of senescence phenotype not addressed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified mitochondrial/ETC dysfunction as an upstream driver of APOE induction, placing APOE within an inflammatory transcriptional response to bioenergetic stress.\",\n      \"evidence\": \"Gene editing of SLC25A transporters and ETC inhibition in iPSC-derived astrocytes and other cells with qRT-PCR/ELISA, plus 5xFAD mouse brain immunoblots\",\n      \"pmids\": [\"37171075\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional link between ETC state and APOE promoter not elucidated\", \"Single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Connected isoform-graded LDLR binding to neuronal lipid pathology, showing impaired LDLR binding (ApoE2, Christchurch) is protective while ApoE4 promotes lysosomal lipofuscinosis and tau fibril retention.\",\n      \"evidence\": \"iPSC-derived human neurons with LDLR binding and cholesteryl ester uptake assays, lipofuscin and tau fibril readouts, and intrahippocampal PUFA-CE-lipApoE4 injection in mice\",\n      \"pmids\": [\"39532095\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking lipofuscin to tau retention not fully resolved\", \"Generalizability of injection sufficiency to physiological aging unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrated that specific APOE coding variants quantitatively shift LDLR binding affinity, providing functional grounding for variant contributions to dysbetalipoproteinemia.\",\n      \"evidence\": \"In vitro VLDL-to-LDLR binding affinity assays with patient-derived variants and NMR lipoprotein particle analysis\",\n      \"pmids\": [\"37051929\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab with limited mechanistic follow-up\", \"In vivo consequences of intermediate-affinity variants not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single protein integrates lipid transport, receptor binding, complement inhibition, and chromatin-destabilizing senescence into the allele-specific risk for Alzheimer's and cardiovascular disease remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified structural-functional model linking isoform differences across all described activities\", \"Relative contribution of each pathway to disease risk in vivo undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [5, 7]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 0]},\n      {\"term_id\": \"GO:0140104\", \"supporting_discovery_ids\": [5, 7, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 3, 8]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": []}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ABCA1\",\n      \"LRP1\",\n      \"LDLR\",\n      \"C1Q\",\n      \"APOA1\",\n      \"PCSK9\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}